Esperion Therapeutics Inc. (NASDAQ: ESPR) is -46.15% lower on its value in year-to-date trading and has touched a low of $0.70 and a high of $3.40 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The ESPR stock was last observed hovering at around $1.65 in the last trading session, with the day’s loss setting it -0.04%.
Currently trading at $1.61, the stock is -6.45% and -15.10% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 3.25 million and changing -2.42% at the moment leaves the stock -29.01% off its SMA200. ESPR registered 64.29% gain for a year compared to 6-month loss of -44.10%. The firm has a 50-day simple moving average (SMA 50) of $1.8804 and a 200-day simple moving average (SMA200) of $2.26855.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The stock witnessed a -12.02% gain in the last 1 month and extending the period to 3 months gives it a -31.20%, and is -2.42% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 5.75% over the week and 6.23% over the month.
Esperion Therapeutics Inc. (ESPR) has around 240 employees, a market worth around $315.91M and $277.79M in sales. Fwd P/E is 8.86. Profit margin for the company is -35.46%. Distance from 52-week low is 130.00% and -52.65% from its 52-week high. The company has generated returns on investments over the last 12 months (-55.65%).
with sales reaching $53.52M over the same period.The EPS is expected to grow by 87.85% this year, but quarterly earnings will post 199.40% year-over-year.
Esperion Therapeutics Inc. (ESPR) Top Institutional Holders
210.0 institutions hold shares in Esperion Therapeutics Inc. (ESPR), with institutional investors hold 70.90% of the company’s shares. The shares outstanding are 196.22M, and float is at 194.16M with Short Float at 19.62%. Institutions hold 70.55% of the Float.
The top institutional shareholder in the company is WASATCH ADVISORS LP with over 16.86 million shares valued at $37.44 million. The investor’s holdings represent 9.9628% of the ESPR Shares outstanding. As of 2024-06-30, the second largest holder is BLACKROCK INC. with 13.98 million shares valued at $31.04 million to account for 8.2617 of the shares outstanding. The other top investors are VANGUARD GROUP INC which holds 10.82 million shares representing 6.3907% and valued at over $24.01 million, while BELLEVUE GROUP AG holds 5.8751 of the shares totaling 9.94 million with a market value of $22.08 million.
Esperion Therapeutics Inc. (ESPR) Insider Activity
The most recent transaction is an insider sale by Koenig Sheldon L., the company’s President and CEO. SEC filings show that Koenig Sheldon L. sold 14,550 shares of the company’s common stock on Sep 17 ’24 at a price of $1.80 per share for a total of $26132.0. Following the sale, the insider now owns 0.75 million shares.
Esperion Therapeutics Inc. disclosed in a document filed with the SEC on Sep 17 ’24 that Warren Eric (Chief Commercial Officer) sold a total of 2,608 shares of the company’s common stock. The trade occurred on Sep 17 ’24 and was made at $1.78 per share for $4650.0. Following the transaction, the insider now directly holds 0.16 million shares of the ESPR stock.
Still, SEC filings show that on Sep 17 ’24, Foody Joanne M. (Officer) Proposed Sale 3,381 shares at an average price of $1.78 for $6015.0. The insider now directly holds shares of Esperion Therapeutics Inc. (ESPR).
